BioNexus Gene Lab (BGLC) Shares Outstanding (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Shares Outstanding (Entity) data on file, last reported at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Entity) changed N/A year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (changed N/A YoY), and the FY2025 full-year result was $1.9 million, up 4.2% from the prior year.
• Shares Outstanding (Entity) advanced to $2.4 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $2.4 million in Q1 2026 to a low of $1.4 million in Q1 2022.
• A 5-year average of $1.7 million and a median of $1.8 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) increased 22.91% in 2023 and dropped 0.01% in 2025, its largest moves.
• Tracing BGLC's Shares Outstanding (Entity) over 5 years: stood at $1.4 million in 2022, then gained by 22.05% to $1.8 million in 2023, then grew by 0.85% to $1.8 million in 2024, then increased by 4.2% to $1.9 million in 2025, then jumped by 30.2% to $2.4 million in 2026.
• Business Quant data shows BGLC's Shares Outstanding (Entity) at $2.4 million in Q1 2026, $1.9 million in Q4 2025, and $1.8 million in Q3 2025.